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Abstract: A holy grail of curing neurodegenerative diseases is to identify the main causes and mechanisms underlying neuronal 
death. Many studies have sought to identify these targets in a wide variety of ways, but a more important task is to identify 
critical molecular targets and their origins. Potential molecular targets include advanced glycation end products (AGEs) that 
can promote neuronal cell death, thereby contributing to neurodegenerative disorders such as Alzheimer disease or Parkinson 
disease. In this study, we showed that AGE-albumin (glycated albumin) is synthesized in microglial cells and secreted in the 
human brain. Our results provide new insight into which microglial cells can promote the receptor for AGE-mediated neuronal 
cell death, eventually leading to neurodegenerative diseases.
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with AGEs in the human brain [5, 6]. However, despite these 
reports, the origin, role, and detailed mechanisms underlying 
the involvement of AGEs in promoting neuronal cell death 
and neurodegeneration are poorly understood. 
The aims of this study were to investigate whether AGEs 




Th   e immortalized human microglial cell line was used for 
in vitro studies. Th   ese cells were maintained at 37°C under 5% 
CO2 in Dulbecco’s modified Eagle’s medium (DMEM with 
high glucose, Gibco, Calsbad, CA, USA) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; Gibco) and 
20 mg/ml gentamicin (Sigma-Aldrich, St. Louis, MO, USA). 
During experiments, human microglial cells were exposed 
to Aβ1-42 (Sigma-Aldrich) at concentrations ranging from 
Introduction
We recently presented that albumin can be synthesized 
and secreted in human brain microglial cells [1]. We also 
showed that the synthesis and secretion of albumin from 
microglial cells is increased by microglial activation following 
exposure to lipopolysaccharide or amyloid β (Aβ) 1-42. 
However, the role of albumin remains unclear. Several studies 
have demonstrated that increased accumulation of advanced 
glycation end products (AGEs) in the brains of patients with 
Alzheimer disease (AD) suggests pathological roles for AGEs 
in neurodegenerative disorders, including AD [2-4]. Activated 
microglial cells and Aβ deposition have been colocalized Anat Cell Biol 2012;45:47-52 Kyunghee Byun, et al 48
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0 to 400 or 5 nM. The cells were then harvested for further 
analysis 6 hours aft  er Aβ1-42 treatment.
Primary culture of human neuronal cells
Primary human neuronal cells were prepared from human 
brain tissues. The methods used for collection and use of 
brain tissue samples were approved by the Ethics Committee 
of the Seoul National University, College of Medicine, Seoul, 
Korea. Cells were dissociated from small pieces of human 
brain cortexes by incubating the tissue in phosphate-buff  ered 
saline (PBS) containing 0.25% trypsin and 40 mg/ml DNase I 
for 30 minutes at 37
oC. Dissociated cells were then suspended 
in DMEM supplemented with 5% FBS, 5% horse serum, 20 
mg/ml gentamicin, and 2.5 mg/ml amphotericin B (feeding 
medium), plated at a density of 10
6 cells/ml in 10-cm culture 
dishes (in 10-ml volume), and maintained at 37
oC in an 
incubator under 5% CO2/95% air atmosphere. Remaining 
neuronal cells were used for apoptosis-related characterization 
following treatment with AGE-albumin or albumin.
Immunocytochemistry (ICC)
Cells were grown on Lab-Tek II slide chambers (Nunc, 
Naperville, IL, USA), rinsed with PBS, fi  xed in methanol for 
15 minutes, and fi  nally rinsed again with PBS. Th  e  fi  xed cells 
on slide chambers were incubated overnight at 4°C with the 
following primary antibodies: rabbit anti-AGE antibody (1 
: 200, Abcam, Cambridge, UK), mouse anti-human-albu-
min antibody (1 : 200, R&D Systems, Minneapolis, MN, 
USA). After overnight incubation, the cells were washed 
three times in PBS, and the slides were then incubated for 1 
hour at room temperature with one of the following secon-
dary antibodies: Alexa Fluor 633 anti-mouse IgG (1 : 500, 
Invitrogen, Carlsbad, CA, USA), Alexa Fluor 488 anti-rabbit 
IgG (1 : 500, Invitrogen), or Alexa Fluor 555 anti-goat IgG (1 
: 500, Invitrogen). Aft  er washing the cells for three 10-minute 
intervals in PBS, cover slips were mounted onto glass slides 
by using Vectashield mounting medium (Vector Laboratories, 
Burlingame, CA, USA), and examined under a laser confocal 
fluorescence microscope (LSM-710, Carl Zeiss, Jena, Ger-
many).
Animals
Adult Sprague-Dawley rats (230-350 g) were used in this 
study. The rats were maintained on a 12-hour light-dark 
cycle, had access to food and water ad libitum, and were accli-
matized for at least 1 week prior to use.
En  torhinal cortex Aβ injection
Animals were anesthetized with ketamine HCl (0.75 mg/
kg body weight) and xylazine (1 mg/kg body weight) prior to 
surgical procedures. For in vivo treatments, Aβ1-42 peptide 
was dissolved in sterile water at a concentration of 400 μM, 
and maintained at 4°C until use. Injection of Aβ1-42 into the 
entorhinal cortex (EC) was done with the aid of a stereotaxic 
instrument by tracing a midline incision into the scalp skin. 
The skull was pierced with a biological electric drill at the 
bregma (posteriorly, 8.3 mm; laterally, 5.4 mm), and the 
30-gauge needle on a 5-μl Hamilton syringe was lowered 
vertically until it reached the target areas (depth, 4.5 mm). 
A total of 5 μl of 200 μM Aβ1-42 solution or 5 μl of PBS was 
injected gradually, at a rate of 1 μl/min, with an automatic 
microinjector. Th   e syringe was then slowly removed, and the 
surgical incisions were sutured with wound clips followed by 
topical treatment with antibiotics.
 
T issue  preparation
Most rats were allowed to recover for a total of 3 days post 
injection. After full recovery, all rats were re-anesthetized 
in the same manner, and perfused transcardially with 100-
200 ml of heparinized saline at 18°C followed by 400 ml of 
4% paraformaldehyde-lysine periodate in 0.1 M sodium 
phosphate buff  er (pH 7.4). Th   e brains were removed, placed 
in the same fi  xative for 4 hours at 4°C, and then, transferred 
into ice-cold 0.1 M PBS containing 20% sucrose. Th  e  brains 
were then cut in a transverse plane at 30-μm thickness with a 
frozen microtome, and then stored at −80°C until use.
Proximity ligation assay (PLA)
PLA was performed in both primary cells and brain 
tissues to visualize the extent (frequency) of protein–protein 
interactions. Target tissues were washed in ice-chilled PBS 
and incubated overnight with mouse anti-human-AGE 
antibody (1 : 200, R&D Systems) and rabbit anti-Aβ antibody 
(1 : 200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
at 4°C. Hoechst and PLA staining was performed using the 
Duolink Detection Kit (Life Technology, Pittsburg, PA, USA) 
according to the manufacturer’s protocol. Tissue specimens 
were mounted with Vectashield mounting media (Vector 
Laboratories) and analyzed using an LSM 710 confocal micro-
scope (Zeiss). Th   e number of in situ PLA signals per cell was 
counted using the semi-automated image analysis program 
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Immunoblot analysis
Whole cell lysates were prepared with RIPA buffer con-
taining 4% CHAPS. Proteins from each group were sepa-
rated in 4-12% polyacrylamide gels (Life Technology) and 
transferred to nitrocellulose membranes. Th   e primary antibo-
dies used were: anti-receptor protein for AGEs (RAGE; 1 : 
200, Santa Cruz), and anti β-actin (1 : 1,000, Cell Signaling 
Technology, Danvers, MA, USA).
Densitometry and statistical analysis
Th   e densitometric intensity of each immunoreactive band 
was determined using a gel digitizing Imagepro soft  ware. Th  e 
data summarized in this report are from at least 3 indepen-
dent experiments, unless stated otherwise. Statistical analyses 
were performed using the Student’s t-test, and P<0.05 was 
considered statistically signifi  cant. 
RESULTS
We fi rst investigated the distribution of AGE and albumin 
in the human microglial cell line and human primary 
microglial cells, respectively. Surprisingly, most AGEs were 
co-localized with albumin, suggesting that AGE-albumin 
could be a major AGE in brain microglial cells (Fig. 1).
Furthermore, to demonstrate the co-localization of 
AGE-albumin and the activated microglial cell marker Iba-
1, we performed triple immunohistochemical staining in 
Aβ-treated human microglial cells and primary human 
microglial cells. Th   e expression levels of AGE were markedly 
increased following Aβ exposure, and most AGE co-localized 
with albumin in the human microglial cells and human 
primary microglial cells. In addition, AGE-albumin and Iba-
1 expression levels were strikingly elevated, and they co-
localized in Aβ-exposed rat brains (Fig. 1).
Relationship between AGE-albumin and Aβ contributing 
to Aβ aggregation was studied. Amyloid plaques in Aβ-
treated rat brains and human AD brains were revealed as 
increased by triple-labeled fluorescent microscopic images 
(Fig. 2). Proximity ligation O-Link analysis was performed 
by fluorescent microscopic images to determine the relative 
extents of interaction between albumin and Aβ in human 
microglial cells and rat brains before and aft  er Aβ treatment, 
as well as human brains from AD individuals, respectively. 
Interaction between AGE-albumin and Aβ, contributing to 
increased synthesis and aggregation of Aβ were increased 
aft  er Aβ treatment (Fig. 2). 
Proximity ligation assay data showed that the amount of 
AGE-RAGE interaction was significantly increased in Aβ-
exposed rat brain neurons (Fig. 3) compared to the neurons 
Fig. 1. Distribution and synthesis 
of advanced glycation end products 
(AGE)-albumin in human microglial 
cells and rat brain. Triple-labeled 
confocal microscopy was used to study 
the distribution and relative levels of 
albumin (ALB, green), AGE (red) and 
a specific marker of microglial cells 
(Iba1, blue) in the human microglial cell 
line, human primary microglial cells, 
and entorhinal cortex of rat brain after 
amyloid β (Aβ) treatment. Scale bar=50 
μm. Anat Cell Biol 2012;45:47-52 Kyunghee Byun, et al 50
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from untreated rat brains. 
Since stress-activated mitogen-activated protein kinases 
(MAPKs) are critical in initiating apop    tosis [7, 8], we monitored 
changes in the levels of MAPKs in human primary neurons. 
Immunohistochemistry analysis showed that, relative to the 
untreated controls, the levels of p38K, p-p38K, stress-activated 
protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK), and 
p-SAPK/JNK were signifi  cantly increased, while the level of 
Fig. 2. Relationship between advanced 
glycation end products (AGE)-albu  min 
(ALB) and amyloid β (Aβ) contri  buting 
to Aβ aggregation. (A) Co-localization 
of albumin (blue), AGE (red), and ThT 
fluorescence (green) in amyloid plaques 
in Aβ-treated rat brains and human 
Alzheimer disease (AD) brains were 
evaluated by triple-labeled fluorescent 
microscopic images. (B) In  terac tion 
between AGE-ALB and Aβ, contributing 
to increased synthesis and aggregation of 
Aβ. Proximity liga  tion O-Link analysis 
was performed by fl  uorescent microscopic 
images to determine the relative extents 
of interac  tion (red spots) between ALB 
and Aβ in human microglial cells and rat 
brains before and after Aβ treatment, as 
well as human brains from normal and 
AD individuals, respectively. Th  e  average 
numbers of blob per cell from each sam-
ple are compared in bar graphs. Scale 
bars=50 μm. Microglial cells synthesize AGE-albumin
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phosphorylated extracellular signal-regulated kinases 1 and 2 
(pERK1/2) was de  creased aft  er human primary neurons were 
exposed to AGE-albumin (Fig. 4).
DISCUSSION
On the basis of observed albumin synthesis in microglial 
cells [1], co-localization of AGEs with Aβ deposits in AD 
brains [2-4], and detection of elevated AGEs [5, 6], we 
hypothesized that AGE-albumin, synthesized in and secreted 
from microglial cells, promotes neuronal cell death. To 
test this hypothesis and to further study the mechanism by 
which AGE-albumin promotes neuronal cell death, we first 
investigated the distribution of AGE and albumin in the 
human microglial cell line and human primary microglial 
cells, respectively. Surprisingly, most AGEs were co-locali-
zed with albumin, suggesting that AGE-albumin could 
be a major AGE in brain microglial cells. Furthermore, 
to demonstrate the co-localization of AGE-albumin and 
the activated microglial cell marker Iba-1, we performed 
triple immunohistochemical staining in Aβ-treated human 
microglial cells and primary human microglial cells. The 
expression levels of AGE were markedly increased following 
Aβ exposure. In addition, AGE-albumin and Iba-1 expression 
Fig. 3. Relative changes in advanced glycation end products (AGE) 
and receptor protein for AGEs (RAGE) interactions. (A) Proximity 
ligation assay was performed using fluorescent microscopy images to 
determine the relative extents of interaction (red spots) between AGE 
and RAGE in the rat brains before or aft  er amyloid β (Aβ) treatment. 
Scale bar=50 μm. (B) Th   e average number of blobs per cell from each 
sample is summarized in bar graphs. 
Fig. 4. Induction of the neuronal mi  to -
gen-activated protein kinases (MAPK) 
pathway by advanced glyca  tion end 
products (AGE)-albumin (ALB). Dou-
ble confocal microscopy images simul-
tan  eously show relative levels of ex  tra-
cellular signal-regulated kinases 1 and 
2 (ERK1/2), pERK1/2, p38K, pp38K, 
stress-activated protein kinase/c-Jun 
NH2-terminal kinase (SAPK/JNK), 
pSAPK/JNK (green), or DAPI (blue) 
in human primary neuronal cells before 
and after AGE-ALB treatment for 6 h. 
Scale bar=50 μm. Anat Cell Biol 2012;45:47-52 Kyunghee Byun, et al 52
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levels were strikingly elevated, and they co-localized in Aβ-
exposed rat brains. On the basis of these results, we concluded 
that AGE-albumin, the most abundant and modified AGE-
protein, is produced largely in the microglial cells of Aβ-
exposed human and rat brains. 
Relationship between AGE-albumin and Aβ contributing 
to Aβ aggregation was studied. Proximity ligation O-Link 
analysis was revealed that the interaction between AGE-
albu  min and Aβ, contributing to increased synthesis and 
aggregation of Aβ were increased aft  er Aβ treatment. 
Increased expression of the neuronal RAGE is highly 
correlated with neuronal death and the development and 
progression of AD [3]. In addition, AGE binds to RAGE in 
primary neurons [4]. Therefore, we also evaluated whether 
AGE-albumin could increase RAGE production, which would 
strongly indicate neuronal apoptosis in AD [3, 9], leading to 
cell death in human primary neurons. 
Immunohistochemistry analysis showed that, relative to 
the untreated controls, the levels of p38K, p-p38K, SAPK/
JNK, and p-SAPK/JNK were signifi  cantly increased, while the 
level of pERK1/2 was decreased aft  er human primary neurons 
were exposed to AGE-albumin. Th   ese data indicate that AGE-
albumin directly activates MAPK pathway, as demonstrated 
previously [10, 11].
In summary, our current data show that AGEs are mos-
tly AGE-albumin in brain. Activated human microglial 
cells produce and secrete AGE-albumin, which promotes 
increased RAGE in neurons. Our results, therefore, provide 
new insight into how microglial cells playing an important 
role in promoting neuronal cell death may contribute to 
neurodegeneration. 
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